NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$25.4b

Last Updated

2021/04/16 08:54 UTC

Data Sources

Company Financials +

Executive Summary

Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Ever Supreme Bio Technology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 6712 is more volatile than 90% of TW stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: 6712's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of TW stocks.


Market Performance


7 Day Return

-4.9%

6712

-1.1%

TW Biotechs

1.4%

TW Market


1 Year Return

198.7%

6712

102.9%

TW Biotechs

62.2%

TW Market

Return vs Industry: 6712 exceeded the TW Biotechs industry which returned 100.4% over the past year.

Return vs Market: 6712 exceeded the TW Market which returned 64% over the past year.


Shareholder returns

6712IndustryMarket
7 Day-4.9%-1.1%1.4%
30 Day9.7%12.9%5.8%
90 Day125.7%42.3%10.5%
1 Year198.7%198.7%104.0%102.9%67.8%62.2%
3 Yearn/a-0.8%-2.5%77.2%56.9%
5 Yearn/a-13.6%-15.7%141.8%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Ever Supreme Bio Technology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ever Supreme Bio Technology undervalued compared to its fair value and its price relative to the market?

32.62x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 6712's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 6712's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 6712 is unprofitable, so we can't compare its PE Ratio to the TW Biotechs industry average.

PE vs Market: 6712 is unprofitable, so we can't compare its PE Ratio to the TW market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 6712's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 6712 is overvalued based on its PB Ratio (32.6x) compared to the TW Biotechs industry average (5.4x).


Future Growth

How is Ever Supreme Bio Technology forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

56.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 6712's forecast earnings growth is above the savings rate (0.8%).

Earnings vs Market: Insufficient data to determine if 6712's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 6712's revenue is forecast to grow faster than the TW market.

High Growth Revenue: Insufficient data to determine if 6712's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 6712's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Ever Supreme Bio Technology performed over the past 5 years?

-41.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 6712 is currently unprofitable.

Growing Profit Margin: 6712 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 6712 is unprofitable, and losses have increased over the past 5 years at a rate of 41.1% per year.

Accelerating Growth: Unable to compare 6712's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6712 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (80.8%).


Return on Equity

High ROE: 6712 has a negative Return on Equity (-13.68%), as it is currently unprofitable.


Financial Health

How is Ever Supreme Bio Technology's financial position?


Financial Position Analysis

Short Term Liabilities: 6712's short term assets (NT$478.6M) exceed its short term liabilities (NT$40.3M).

Long Term Liabilities: 6712's short term assets (NT$478.6M) exceed its long term liabilities (NT$37.2M).


Debt to Equity History and Analysis

Debt Level: 6712 is debt free.

Reducing Debt: 6712 has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 6712 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: 6712 has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 46% each year.


Dividend

What is Ever Supreme Bio Technology current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 6712's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 6712's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 6712's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 6712's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 6712's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Ever Supreme Bio Technology has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10%.


Top Shareholders

Company Information

Ever Supreme Bio Technology Co., Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ever Supreme Bio Technology Co., Ltd
  • Ticker: 6712
  • Exchange: GTSM
  • Founded: 2016
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$25.364b
  • Shares outstanding: 61.61m
  • Website: https://www.ever-supreme.com.tw

Number of Employees


Location

  • Ever Supreme Bio Technology Co., Ltd
  • Room A, No. 573, Taiwan Boulevard
  • 10th Floor
  • Taichung
  • 403
  • Taiwan

Listings


Biography

Ever Supreme Bio Technology Co., Ltd engages in the research and development of cell gene therapies based on immune cells and stem cells. Its products in development include UMSC01, a drug candidate in Pha...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/16 08:54
End of Day Share Price2021/04/15 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.